ClinicalTrials.gg
Not yet recruitingNCT07848893Updated Sep 30, 2026

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Advanced Gynecological Tumors.

A Phase 2 interventional study of RNK08954 in Advanced Gynecologic Malignancies, sponsored by Ranok Therapuetics Co. Ltd.. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Ranok Therapuetics Co. Ltd. · Phase 2, Interventional, and Treatment

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This is a multicenter, open-label, phase II clinical study to evaluate the safety and preliminary efficacy of RNK08954 in patients with advanced gynecological tumors

02

Conditions studied

  • Advanced Gynecologic Malignancies
03

In context

Lead sponsor

This is the only study on the registry with Ranok Therapuetics Co. Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must voluntarily agree to participate in the trial and sign a written form.
  • Age ≥ 18 years, female.
  • Physical condition score score 0-1 points.
  • Expected survival ≥ 12 weeks.
  • At the time of study enrollment, according to the solid tumor efficacy evaluation criteria (RECIST1.1), imaging diagnosis had at least one .
  • Have adequate hematologic and end-organ function, with laboratory test results within required parameters within 7 days prior to the first dose.
  • or cytologically confirmed advanced gynecological (including ovarian cancer, endometrial cancer, cervical cancer, etc.) with disease progression after at least one prior systemic therapy.
  • Presence of a KRAS G12D mutation.
  • Participants and their partners agree to comply with the requirement from the time of screening until 6 months after the final administration of the trial drug and agree to use effective non-pharmacological contraceptive measures during the trial period.

Exclusion criteria

Exclusion Criteria:

  • Presence of uncontrolled symptomatic central nervous system ; including , spinal cord metastasis, or brainstem metastasis.
  • Presence of symptomatic and uncontrolled body cavity effusions.
  • Clinical condition with an acute and significant decline, including, but not limited to, a decrease in performance status to >1 within 72 hours prior to the baseline visit and initiation of study treatment, a weight loss of ≥10% during the screening period, or a \<18.0 kg/m².
  • Except for certain circumstances, a history of malignant tumors other than the inclusion diagnosis within 2 years prior to the first administration of the drug.
  • History of known severe or uncontrolled cardiovascular or cerebrovascular disease that requires treatment.
  • Having received other drugs or systemic anti-tumor therapies not yet approved for marketing prior to the first dose, with the interval from the last administration or treatment being less than 4 weeks or 5 half-lives.
  • Having undergone major surgery or experienced significant trauma within 4 weeks prior to the first dose, or requiring elective surgery during the trial period.
  • The presence of severe non-healing wounds, ulcers, fractures, etc., within 4 weeks prior to the first dose.
  • Severe infection occurred within 4 weeks prior to the first dose, including but not limited to hospitalization due to infectious complications, bacteremia, or severe pneumonia; presence of systemic active infection within 2 weeks prior to the first dose requiring systemic anti-infective therapy.
  • Presence of active tuberculosis infection at the time of screening.
  • Positive for surface antigen (HBsAg) at screening with hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 2000 IU/mL. Positive for antibody (HCV-Ab) and positive for hepatitis C virus (HCV) ribonucleic acid (RNA) at screening.
  • Known infection with (HIV) or active Treponema pallidum.
  • Currently taking any medication that may have drug-drug interactions with RNK08954.
  • Presence of any toxicity from previous antitumor therapies that has not recovered to Grade ≤1.
  • Unable to take oral medications, or presence of gastrointestinal conditions that, in the investigator's judgment, significantly affect drug absorption, such as dysphagia, treatment- nausea and vomiting, or malabsorption syndrome.
  • Prior total gastrectomy or total small bowel resection, symptomatic inflammatory bowel disease, partial or complete intestinal obstruction, or any other severe acute or chronic gastrointestinal disease that may increase the risk of study participation, including abdominal fistula, gastrointestinal perforation, or history of peptic ulcer disease.
  • Prior hematopoietic stem cell transplantation or solid organ transplantation.
  • History of interstitial lung disease (ILD)/non-infectious pneumonitis requiring therapy within 6 months prior to the first dose, or currently has ILD/non-infectious pneumonitis, or suspected ILD/non-infectious pneumonitis (e.g., idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonia, etc.), or other moderate to severe acute or chronic pulmonary disease history.
  • History of psychotropic substance abuse or drug addiction.
  • Severe psychological or psychiatric disorders that may affect the participant's compliance with study procedures.
  • Active disease that required systemic treatment within the past 2 years, or autoimmune disease that, in the investigator's judgment, is at risk of recurrence or planned for treatment.
  • Known or intolerance to RNK08954 or any of its ; or history of severe allergic disposition.
  • Other situations that the researchers believe should not be included.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    RNK08954

    Drug: RNK08954

Interventions

  • RNK08954 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

06

What researchers measure

Primary outcomes

  1. ORR

    ORR was evaluated by RECIST v1.1.

    Time frame: Up to 2 years

Secondary outcomes

  1. PFS

    Progression-free survival (PFS) is assessed by investigators using RECIST 1.1 criteria.

    Time frame: up to 2 years

  2. DOR

    Duration of response (DoR) is assessed by investigators using RECIST 1.1 criteria.

    Time frame: Up to 2 years

  3. DCR

    Disease control rate (DCR) is assessed by investigators using RECIST 1.1 criteria.

    Time frame: Up to 2 years

  4. OS

    Overall Survival (OS)

    Time frame: Up to 3 years

  5. The incidence and severity of AEs and SAEs

    The incidence and severity of AEs and SAEs

    Time frame: Up to 2 years

  6. CL/F

    apparent clearance

    Time frame: Up to 2 years

  7. Vc/F

    apparent central volume of distribution

    Time frame: up to 2 years

  8. AUC

    area under the concentration-time curve

    Time frame: up to 2 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Aug 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 30, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07848893
Lead sponsor
Ranok Therapuetics Co. Ltd.
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Jianghua Chen
Contact
chenjianghua@ranoktherapeutics.com
86-0571-86630936

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RNK08954

Start the discussion